Tradestie Institutional Equity Comparison Engine

HHS vs TTI โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

HHS Overall Edge

HHS Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Harte Hanks, Inc. (HHS) driven by superior Valuation, Momentum & Technical while TTI counters with relative strength in Growth & Margin, Options & Structure. Fundamentally, HHS trades at 14.3x Forward P/E with -3.2% operating margin (-1.7% YoY revenue) versus TTI at 20.7x Forward P/E and 7.4% operating margin (+9.6% YoY). In options structure, HHS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against TTI sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner HHS
HHS 14.3x vs TTI 20.7x Fwd P/E
Growth & Margin Winner TTI
Op Margin -3.2% vs 7.4% ยท YoY -1.7% vs +9.6%
Momentum & Technical Winner HHS
1Y +9.1% vs -17.4% ยท 52W Pos 69% vs 17%
Options & Structure Winner TTI
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (<1st %ile IV)
HHS US Equity
Harte Hanks, Inc.
Services-Direct Mail Advertising Services
$3.85
-3.99% 1D
Market Cap $29.9M
1M Return -10.26%
1Y Return +9.07%
Forward P/E 14.3x
Unified AI Score
61.8 / 100 BUY
Tech 76.0 Fund 61.0 Flow 50.0 Mom 54.0
TTI NYSE
TETRA Technologies, Inc.
Crude Petroleum & Natural Gas
$6.20
-2.97% 1D
Market Cap $948.5M
1M Return +16.54%
1Y Return -17.44%
Forward P/E 20.7x
Unified AI Score
35.2 / 100 SELL
Tech 8.0 Fund 33.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: HHS +9.07% TTI -17.44% Spread: +52.53 pp (HHS Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
HHS TTM Op. Margin: -3.2% TTI TTM Op. Margin: 7.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HHS vs TTI. Trailing 12-month operating profitability (HHS -3.2% vs TTI 7.4%) and valuation multiples (HHS 14.3x vs TTI 20.7x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: HHS (5) vs TTI (5)
Institutional Metric HHS TTI Criterion Row Winner
Market Capitalization Scale $29.9M $948.5M Larger Scale TTI
Trailing P/E Ratio Valuation 14.3x 91.3x Lower Multiple HHS
Forward P/E Ratio Valuation 14.3x 20.7x Lower Multiple HHS
Revenue Growth (YoY) Growth -1.7% +9.6% Higher Growth TTI
Operating Margin (TTM) Profitability -3.2% 7.4% Higher Margin TTI
Net Profit Margin Profitability -3.7% 1.4% Higher Margin TTI
Return on Equity (ROE) Capital Efficiency -30.4% 2.9% Higher ROE TTI
52-Week Range Position Momentum 69% ($2โ€“$5) 17% ($5โ€“$13) Stronger Trend HHS
Beta / 30D Volatility Risk Regime 0.49ฮฒ ยท 46% Vol 1.45ฮฒ ยท 61% Vol Lower Realized Risk HHS
Unified Institutional Score Composite Signal 61.8 / 100 (BUY) 35.2 / 100 (SELL) Higher Composite HHS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full HHS vs TTI Buy Guide
HHS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live HHS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
TTI UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live TTI Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither HHS nor TTI registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.